Skip to Content

Savient Pharmaceuticals to Release Top-Line Results from Puricase Phase 3 Trials in Treatment-Failure Gout on December 13, 2007

EAST BRUNSWICK, N.J.--(BUSINESS WIRE)--Dec 13, 2007 - Savient Pharmaceuticals, Inc. (NASDAQ:SVNT) announces that the Company will make public top-line results from its two pivotal Phase 3 clinical trials with Puricase(R) (pegloticase) for patients with treatment-failure gout via a news release to be issued at approximately 6:00 a.m. eastern time on December 13, 2007. At 8:00 a.m. eastern time that same day, Christopher Clement, President and Chief Executive Officer and Zeb Horowitz, M.D., Chief Medical Officer, will host an investment community conference call to discuss the clinical results and to answer questions.

Those interested in listening to the conference call live via the Internet may do so by visiting the Investor Relations section of Savient Pharmaceuticals' website at The webcast will be available for 14 days on the Company website beginning approximately one hour after the conclusion of the conference call.

A telephone replay will be available from 11:00 a.m. eastern time on December 13 through December 23rd at 11:59 p.m. eastern time by dialing (800) 642-1687 (domestic) or (706) 645-9291 (international) and entering conference ID number 27984783.

Puricase is a pegylated recombinant mammalian urate oxidase being developed to control hyperuricemia and its clinical consequences in patients for whom conventional therapy is contraindicated or has been ineffective. At this time there is no alternative therapeutic option for the management of treatment-failure gout patients other than symptomatic relief. Savient has licensed worldwide rights to the technology related to Puricase from Duke University and Mountain View Pharmaceuticals, Inc.


Savient Pharmaceuticals is a biopharmaceutical company engaged in developing and distributing pharmaceutical products that target unmet medical needs in both niche and broader markets. The Company's lead product development candidate, Puricase(R) for treatment-failure gout, has reported positive Phase 1 and 2 clinical data. Patient dosing in the Phase 3 clinical studies began in June 2006; patient enrollment was completed in March 2007, and the Phase 3 clinical studies were completed in October 2007. Pegloticase became the official generic name for Puricase assigned by the USAN Council replacing the previously used name of PEG-uricase. Savient's experienced management team is committed to advancing its pipeline and expanding its product portfolio by in-licensing late-stage compounds and exploring co-promotion and co-development opportunities that fit the Company's expertise in specialty pharmaceuticals and biopharmaceuticals with an initial focus in rheumatology. Savient also manufactures and supplies Oxandrin(R) (oxandrolone tablets, USP) CIII in the U.S. Puricase is a registered trademark of Mountain View Pharmaceuticals, Inc. Further information on Savient is available at



Savient Pharmaceuticals, Inc.
Mary Coleman, Director, Investor Relations, 732-418-9300
Lippert/Heilshorn & Associates
Anne Marie Fields, 212-838-3777

Posted: December 2007